If You Invested in Talphera Inc (TLPH)
Custom Calculation
Choose your own date and amount for TLPH$1,000 Investment Over Time
TLPH vs S&P 500Year-by-Year Returns
TLPH annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2017 | $51.00 | $40.60 | -20.4% | -20.4% |
| 2018 | $41.00 | $46.20 | +12.7% | -9.4% |
| 2019 | $49.60 | $42.20 | -14.9% | -17.3% |
| 2020 | $41.40 | $24.80 | -40.1% | -51.4% |
| 2021 | $25.00 | $11.20 | -55.2% | -78.0% |
| 2022 | $12.20 | $2.26 | -81.5% | -95.6% |
| 2023 | $2.22 | $0.74 | -66.7% | -98.5% |
| 2024 | $0.74 | $0.52 | -29.2% | -99.0% |
| 2025 | $0.59 | $1.14 | +93.2% | -97.8% |
| 2026 | $1.16 | $0.85 | -26.9% | -98.3% |
About Talphera Inc
Pharmaceutical Preparations · NASDAQ
Talphera, Inc. develops and seeks to commercialize specialty pharmaceutical therapies for use in medically supervised settings. The company’s disclosed business centers on product candidates used in controlled clinical or hospital environments, with its lead program focused on anticoagulation for extracorporeal blood circuits used during renal replacement therapy.
The company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat. Talphera describes Niyad as an investigational anticoagulant for the extracorporeal circuit, and company materials state that it is being studied under an investigational device exemption. Niyad has received Breakthrough Device Designation from the U.S. Food and Drug Administration. The clinical program is tied to continuous renal replacement therapy, a critical-care setting involving extracorporeal blood filtration.
Talphera’s portfolio is described as including nafamostat product candidates and pre-filled syringe product candidates. Nafamostat candidates identified for the company include Niyad and LTX-608. The company’s operating model is based on advancing specialized therapeutic candidates through development, regulatory and clinical processes, and potential commercialization in medically supervised care settings.
Talphera is incorporated in Delaware and is headquartered in San Mateo, California. Its common stock trades on The Nasdaq Capital Market under the symbol TLPH. Public disclosures also show financings involving common stock and pre-funded warrants, equity incentive plans, stockholder voting matters, board governance and Nasdaq listing-compliance notices.
The company’s reporting history reflects a narrowed business focus following the divestment of DSUVIA, which Talphera has treated as a discontinued operation in its financial reporting. The current public-company profile is therefore centered on specialty pharmaceutical development, the Niyad program, clinical and regulatory activities related to medically supervised use, and the capital and governance matters associated with a small public life-sciences issuer.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Talphera Inc investment returns
How much would $1,000 invested in Talphera Inc be worth today?
If you invested $1,000 in Talphera Inc (TLPH) 10 years ago on 2016-05-18, your investment would be worth $13 today, representing a -98.7% total return, growing at a compounded rate of -35.1% per year (CAGR).
Has Talphera Inc outperformed the S&P 500?
Over the past 10 years, TLPH returned -98.7% compared to +260.7% for the S&P 500, underperforming the benchmark by 359.4 percentage points.
What is Talphera Inc's average annual return?
The compound annual growth rate (CAGR) of TLPH over the past 10 years is -35.1%, growing at a compounded rate each year. Individual years vary significantly — TLPH's best recent year was 2025 (+93.2%) and worst was 2022 (-81.5%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
